UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) December 19, 2013

 

Bio-Reference Laboratories, Inc.

(Exact name of registrant as specified in its charter)

 

New Jersey

 

0-15266

 

22-2405059

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

481 Edward H. Ross Drive, Elmwood Park, NJ

 

07407

(Address of principal executive offices)

 

(Zip Code)

 

(201) 791-2600

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14-d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

ITEM 2.02           RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

On December 19, 2013, Bio-Reference Laboratories, Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1.  The Company will hold its earnings call to discuss its results for the fourth quarter and year end for 2013 today at 10:30 a.m. ET.  A copy of the prepared comments of the Company for that call is attached hereto as Exhibit 99.2.

 

The corresponding exhibits listed under Item 9.01 of this Current Report on Form 8-K are not filed with the Securities and Exchange Commission or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing, and is incorporated herein solely for purposes of this Item 2.02 of Form 8-K.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d)           Exhibits.

 

99.1        Press release, dated December 19, 2013

 

99.2        Prepared Comments of Company for December 19, 2013 Conference Call

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 19, 2013

BIO-REFERENCE LABORATORIES, INC.

 

 

 

 

 

By:

/S/ Marc D. Grodman, MD

 

 

Name: Marc D. Grodman, MD

 

 

Title: Chairman of the Board, President and

 

 

Chief Executive Officer

 

3